Analysis of Intratumoral Heterogeneity in Myelodysplastic Syndromes with Isolated del(5q) Using a Single Cell Approach

被引:7
作者
Acha, Pamela [1 ]
Palomo, Laura [1 ]
Fuster-Tormo, Francisco [1 ]
Xicoy, Blanca [2 ]
Mallo, Mar [1 ,3 ]
Manzanares, Ana [1 ]
Grau, Javier [2 ]
Marce, Silvia [2 ]
Granada, Isabel [2 ]
Rodriguez-Luaces, Marta [4 ]
Diez-Campelo, Maria [5 ]
Zamora, Lurdes [2 ]
Sole, Francesc [1 ]
机构
[1] Univ Autonoma Barcelona, ICO Hosp Germans Trias & Pujol, Inst Recerca Leucemia Josep Carreras, MDS Grp, Badalona 08916, Spain
[2] Univ Autonoma Barcelona, Inst Recerca Leucemia Josep Carreras, ICO Hosp Germans Trias & Pujol, Hematol Serv, Badalona 08916, Spain
[3] Univ Autonoma Barcelona, ICO Hosp Germans Trias & Pujol, Inst Recerca Leucemia Josep Carreras, Microarrays Unit, Badalona 08916, Spain
[4] ICO Hosp Verge Cinta Tortosa, Hematol Serv, Tarragona 43500, Spain
[5] Hosp Univ Salamanca, Hematol Serv, Salamanca 37007, Spain
关键词
myelodysplastic syndromes; single cell; intratumoral heterogeneity; CLONAL EVOLUTION; STEM-CELLS; LENALIDOMIDE; MUTATIONS; MDS; 5Q;
D O I
10.3390/cancers13040841
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Simple Summary Myelodysplastic syndromes (MDS) are a heterogeneous group of clonal hematopoietic stem cell malignancies characterized by ineffective differentiation of one or more bone marrow cell lineages. Only 50% of patients with de novo MDS will be found to have cytogenetic abnormalities, of which del(5q) is the most common. In 10% of MDS cases, del(5q) is found as a sole abnormality. In this work, a single cell approach was used to analyze intratumoral heterogeneity in four patients with MDS with isolated del(5q). We were able to observe that an ancestral event in one patient can appear as a secondary hit in another one, thus reflecting the high intratumoral heterogeneity in MDS with isolated del(5q) and the importance of patient-specific molecular characterization. Myelodysplastic syndromes (MDS) are a heterogeneous group of hematological diseases. Among them, the most well characterized subtype is MDS with isolated chromosome 5q deletion (MDS del(5q)), which is the only one defined by a cytogenetic abnormality that makes these patients candidates to be treated with lenalidomide. During the last decade, single cell (SC) analysis has emerged as a powerful tool to decipher clonal architecture and to further understand cancer and other diseases at higher resolution level compared to bulk sequencing techniques. In this study, a SC approach was used to analyze intratumoral heterogeneity in four patients with MDS del(5q). Single CD34+CD117+CD45+CD19- bone marrow hematopoietic stem progenitor cells were isolated using the C1 system (Fluidigm) from diagnosis or before receiving any treatment and from available follow-up samples. Selected somatic alterations were further analyzed in SC by high-throughput qPCR (Biomark HD, Fluidigm) using specific TaqMan assays. A median of 175 cells per sample were analyzed. Inferred clonal architectures were relatively simple and either linear or branching. Similar to previous studies based on bulk sequencing to infer clonal architecture, we were able to observe that an ancestral event in one patient can appear as a secondary hit in another one, thus reflecting the high intratumoral heterogeneity in MDS del(5q) and the importance of patient-specific molecular characterization.
引用
收藏
页码:1 / 17
页数:17
相关论文
共 42 条
  • [1] Clinical Effect of Point Mutations in Myelodysplastic Syndromes
    Bejar, Rafael
    Stevenson, Kristen
    Abdel-Wahab, Omar
    Galili, Naomi
    Nilsson, Bjoern
    Garcia-Manero, Guillermo
    Kantarjian, Hagop
    Raza, Azra
    Levine, Ross L.
    Neuberg, Donna
    Ebert, Benjamin L.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (26) : 2496 - 2506
  • [2] Myelodysplastic syndrome progression to acute myeloid leukemia at the stem cell level
    Chen, Jiahao
    Kao, Yun-Ruei
    Sun, Daqian
    Todorova, Tihomira I.
    Reynolds, David
    Narayanagari, Swathi-Rao
    Montagna, Cristina
    Will, Britta
    Verma, Amit
    Steidl, Ulrich
    [J]. NATURE MEDICINE, 2019, 25 (01) : 103 - +
  • [3] Architectural and functional heterogeneity of hematopoietic stem/progenitor cells in non-del(5q) myelodysplastic syndromes
    Chesnais, Virginie
    Arcangeli, Marie-Laure
    Delette, Caroline
    Rousseau, Alice
    Guermouche, Helene
    Lefevre, Carine
    Bondu, Sabrina
    Diop, M'boyba
    Cheok, Meyling
    Chapuis, Nicolas
    Legros, Laurence
    Raynaud, Sophie
    Willems, Lise
    Bouscary, Didier
    Lauret, Evelyne
    Bernard, Olivier A.
    Kosmider, Olivier
    Pflumio, Francoise
    Fontenay, Michaela
    [J]. BLOOD, 2017, 129 (04) : 484 - 496
  • [4] Effect of lenalidomide treatment on clonal architecture of myelodysplastic syndromes without 5q deletion
    Chesnais, Virginie
    Renneville, Aline
    Toma, Andrea
    Lambert, Jerome
    Passet, Marie
    Dumont, Florent
    Chevret, Sylvie
    Lejeune, Julie
    Raimbault, Anna
    Stamatoullas, Aspasia
    Rose, Christian
    Beyne-Rauzy, Odile
    Delaunay, Jacques
    Solary, Eric
    Fenaux, Pierre
    Dreyfus, Francois
    Preudhomme, Claude
    Kosmider, Olivier
    Fontenay, Michaela
    [J]. BLOOD, 2016, 127 (06) : 749 - 760
  • [5] Clonal evolution in myelodysplastic syndromes
    da Silva-Coelho, Pedro
    Kroeze, Leonie I.
    Yoshida, Kenichi
    Koorenhof-Scheele, Theresia N.
    Knops, Ruth
    van de Locht, Louis T.
    de Graaf, Aniek O.
    Massop, Marion
    Sandmann, Sarah
    Dugas, Martin
    Stevens-Kroef, Marian J.
    Cermak, Jaroslav
    Shiraishi, Yuichi
    Chiba, Kenichi
    Tanaka, Hiroko
    Miyano, Satoru
    de Witte, Theo
    Blijlevens, Nicole M. A.
    Muus, Petra
    Huls, Gerwin
    van der Reijden, Bert A.
    Ogawa, Seishi
    Jansen, Joop H.
    [J]. NATURE COMMUNICATIONS, 2017, 8
  • [6] Single-cell mutational profiling enhances the clinical evaluation of AML MRD
    Ediriwickrema, Asiri
    Aleshin, Alexey
    Reiter, Johannes G.
    Corces, M. Ryan
    Kohnke, Thomas
    Stafford, Melissa
    Liedtke, Michaela
    Medeiros, Bruno C.
    Majeti, Ravindra
    [J]. BLOOD ADVANCES, 2020, 4 (05) : 943 - 952
  • [7] The novel mechanism of lenalidomide activity
    Fink, Emma C.
    Ebert, Benjamin L.
    [J]. BLOOD, 2015, 126 (21) : 2366 - 2369
  • [8] Treatment of Anemia in Transfusion-Dependent and Non-Transfusion-Dependent Lower-Risk MDS: Current and Emerging Strategies
    Germing, Ulrich
    Oliva, Ester N.
    Hiwase, Devendra
    Almeida, Antonio
    [J]. HEMASPHERE, 2019, 3 (06):
  • [9] Patients with del(5q) MDS who fail to achieve sustained erythroid or cytogenetic remission after treatment with lenalidomide have an increased risk for clonal evolution and AML progression
    Goehring, Gudrun
    Giagounidis, Aristoteles
    Buesche, Guntram
    Kreipe, Hans Heinrich
    Zimmermann, Martin
    Hellstroem-Lindberg, Eva
    Aul, Carlo
    Schlegelberger, Brigitte
    [J]. ANNALS OF HEMATOLOGY, 2010, 89 (04) : 365 - 374
  • [10] Revised International Prognostic Scoring System for Myelodysplastic Syndromes
    Greenberg, Peter L.
    Tuechler, Heinz
    Schanz, Julie
    Sanz, Guillermo
    Garcia-Manero, Guillermo
    Sole, Francesc
    Bennett, John M.
    Bowen, David
    Fenaux, Pierre
    Dreyfus, Francois
    Kantarjian, Hagop
    Kuendgen, Andrea
    Levis, Alessandro
    Malcovati, Luca
    Cazzola, Mario
    Cermak, Jaroslav
    Fonatsch, Christa
    Le Beau, Michelle M.
    Slovak, Marilyn L.
    Krieger, Otto
    Luebbert, Michael
    Maciejewski, Jaroslaw
    Magalhaes, Silvia M. M.
    Miyazaki, Yasushi
    Pfeilstoecker, Michael
    Sekeres, Mikkael
    Sperr, Wolfgang R.
    Stauder, Reinhard
    Tauro, Sudhir
    Valent, Peter
    Vallespi, Teresa
    van de Loosdrecht, Arjan A.
    Germing, Ulrich
    Haase, Detlef
    [J]. BLOOD, 2012, 120 (12) : 2454 - 2465